Application of Percutaneous Balloon Mitral Valvuloplasty in Patients of Rheumatic Heart Disease Mitral Stenosis Combined with Tricuspid Regurgitation

Background: Tricuspid regurgitation (TR) is frequently associated with severe mitral stenosis (MS), the importance of significant TR was often neglected. However, TR influences the outcome of patients. The aim of this study was to investigate the efficacy and safety of percutaneous balloon mitral valvuloplasty (PBMV) procedure in rheumatic heart disease patients with mitral valve (MV) stenosis and tricuspid valve regurgitation. Methods: Two hundred and twenty patients were enrolled in this study due to rheumatic heart disease with MS combined with TR. Mitral balloon catheter made in China was used to expand MV. The following parameters were measured before and after PBMV: MV area (MVA), TR area (TRA), atrial pressure and diameter, and pulmonary artery pressure (PAP). The patients were followed for 6 months to 9 years. Results: After PBMV, the MVAs increased significantly (1.7 0.3 cm (2) vs. 0.9 0.3 cm (2) , P < 0.01); TRA significantly decreased (6.3 1.7 cm (2) vs. 14.2 6.5 cm (2) , P < 0.01), right atrial area (RAA) decreased significantly (21.5 4.5 cm (2) vs. 25.4 4.3 cm (2) , P < 0.05), TRA/RAA (%) decreased significantly (29.3 3.2% vs. 44.2 3.6%, P < 0.01). TR velocity (TRV) and TR continue time (TRT) as well as TRV x TRT decreased significantly (183.4 9.4 cm/s vs. 254.5 10.7 cm/s, P < 0.01; 185.7 13.6 ms vs. 238.6 11.3 ms, P < 0.01; 34.2 5.6 cm vs. 60.7 8.5 cm, P < 0.01, respectively). The postoperative left atrial diameter (LAD) significantly reduced (41.3 6.2 mm vs. 49.8 6.8 mm, P < 0.01) and the postoperative right atrial diameter (RAD) significantly reduced (28.7 5.6 mm vs. 46.5 6.3 mm, P < 0.01); the postoperative left atrium pressure significantly reduced (15.6 6.1 mmHg vs. 26.5 6.6 mmHg, P < 0.01), the postoperative right atrial pressure decreased significantly (13.2 2.4 mmHg vs. 18.5 4.3 mmHg, P < 0.01). The pulmonary arterial pressure decreased significantly after PBMV (48.2 10.3 mmHg vs. 60.6 15.5 mmHg, P < 0.01). The symptom of chest tightness and short of breath obviously alleviated. All cases followed-up for 6 months to 9 years (average 75 32 months), 2 patients with severe regurgitation died (1 case of massive cerebral infarction, and 1 case of heart failure after 6 years and 8 years, respectively), 2 cases lost access. At the end of follow-up, MVA has been reduced compared with the postoperative (1.4 0.4 cm (2) vs. 1.7 0.3 cm (2) , P < 0.05); LAD slightly increased compared with the postoperative (45.2 5.7 mm vs. 41.4 6.3 mm, P < 0.05), RAD slightly also increased compared with the postoperative (36.1 6.3 mm vs. 28.6 5.5 mm, P < 0.05), but did not recover to the preoperative level. TRA slightly increased compared with the postoperative, but the difference was not statistically significant (P > 0.05). The PAP and left ventricular ejection fraction appeared no statistical difference compared with the postoperative (P > 0.05), the remaining patients without serious complications. Conclusions: PBMV is a safe and effective procedure for MS combined with TR in patients of rheumatic heart disease. It can alleviate the symptoms and reduce the size of TR. It can also improve the quality-of-life and prognosis. Its recent and mid-term efficacy is certain. While its long-term efficacy remains to be observed.